Comparison of the Impact of Dialysis Treatment Type on Patient Survival
A Prospective, Randomized, Multicenter, Open Label, Interventional Pilot Study To Compare Mortality, Morbidity and QOL in Hemodialysis Versus Peritoneal Dialysis Subjects
As the influence of type of dialysis on survival of end stage renal disease (ESRD) patients remains unanswered, the present study is designed (randomized, prospective, multicenter, interventional) to assess clinical outcomes, and compare mortality, morbidity, Quality of Life (QOL) and cost effectiveness between maintenance In-center Hemodialysis (ICHD) and Continuous Ambulatory Peritoneal dialysis (CAPD). These data will ultimately bring clarity on whether or not any difference in patient survival exists between the two modalities.
In order to test the feasibility of patients' willingness to be randomized to two different modality groups and retained in the randomized group, a pilot study is planned before the conduct of a main study.
This pilot study comprises of a 6 months study, plus a 6 months observation if there is possibility to switch the patients into the main study.
All ESRD patients requiring dialysis treatment within 8 weeks after a pre-study visit will be recorded in each site. Patients who provide written inform consent for collecting relevant information will be screened using certain inclusion/exclusion criteria. Eligible patients will undergo a standardized education regarding ESRD and treatment options. Thereafter the patient will be required to provide a second inform consent allowing for randomization and entrance into the study. Eligible patient will be randomized to either PD or HD treatment.
The patients will be followed for a period of 6 months, during which patients will be treated with PD or HD as prescribed at each site, while meeting the dialysis adequacy and other indicators. For the first 3 months monthly visits are required, after which an every 3 months visit is planned.
In this pilot study, the main objective is to assess the willingness of ESRD patients to be randomized to either PD or HD treatment; thereby determining if an adequate number of eligible patients can be recruited for a future large-scale study.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Anticipé)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
-
Beijing, Chine
- Bejing No.3 Hospital
-
Shanghai, Chine
- Renji Hospital, Shanghai
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male or female patients who are at least 18 years of age.
- Patients who have read, understood and given written informed consent after the nature of the study has been explained.
- Patients who have a diagnosis of ESRD (GFR ≤ 10 ml/min), without a permanent access for dialysis.
- Patients who are able to comprehend a modality education program.
- Patients who are judged as capable of being trained for home based PD.
- Patients as justified by their physicians requiring dialysis treatment within 6 weeks after randomization (Patients who require urgent temporary dialysis before randomization may also be eligible for recruitment after being stabilized with temporary HD or PD)
- Patients who are expected to remain on dialysis for at least 6 months.
- Patients must have a negative HIV test at screening. -
Exclusion Criteria:
- Patients that have already received a permanent catheter or access that is intended for permanent therapy use before receiving modality information, or have already received permanent dialysis (If an access is present within 4 weeks prior to screening for back-up purposes, or for acute treatment for life threatening uremic symptoms, electrolyte abnormalities or fluid overload, this does not exclude the patient from enrollment).
- Patients who previously have received renal transplantation and are still prescribed immunosuppressive therapy.
- Patients who are unwilling or unable to follow the protocol.
- Patients with concomitant participation in any other interventional study, or who have received any investigational drug, biologic or device within five half-lives of the physiological action or 30 days, whichever is longer, prior to screening.
Patients justified as not eligible for either PD or HD due to:
- PD: documented extensive intra-peritoneal adhesions, severe infective skin disorder, or other situation contradicting PD (eg., active inflammatory bowel disease)
- HD: severe cardiac instability and inability to a gain permanent vascular access.
- Patients who have a history of drug or alcohol abuse within the six months prior to entering the study
- Patients who have active systemic infections, such as tuberculosis, septicemia or systemic fungal infections.
- Patients who have malignancies requiring active chemotherapy or radiation therapy.
- The presence of other terminal illness likely to cause death within 6 months
- Patients who have any other serious acute or active conditions that in the investigator's opinion would preclude their participation in the study.
- Female patients who are pregnant, lactating or planning on becoming pregnant during the study period.
- Patients who are allergic to starch-based polymers, maltose or isomaltose
- Patients who have glycogen storage disease.
- Patients who have a significant psychiatric disorder or mental disability that could interfere with the patient's ability to provide informed consent and/or comply with protocol procedures -
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: 1, PD
Peritoneal Dialysis
|
Peritoneal Dialysis: CAPD; Hemodialysis: 3 times/week
|
|
Comparateur actif: 2, HD
Hemodialysis
|
Peritoneal Dialysis: CAPD; Hemodialysis: 3 times/week
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
To assess willingness of ESRD patients to be randomized to either PD or HD; thereby determining if an adequate number of eligible patients can be recruited for a future large-scale study.
Délai: August 2008
|
August 2008
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Jia-Qi QIAN, Prof, Center for one Baxter -Tel: 8004229837
- Chercheur principal: Tao Wang, Prof, Center for one Baxter -Tel: 8004229837
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SurvivalHD/PDFinal 28/03/2007
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .